-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $330

Benzinga·11/12/2026 13:00:33
Listen to the news
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $310 to $330.